Search results
Added:
1 year ago
Added:
2 years ago
Source:
Radcliffe Cardiology
Find out what's hot at TCT in this preview from Prof Nicolas Van Mieghem and Dr Joost Daemen
The Cardiovascular Research Foundation (CRF) has unveiled the late-breaking clinical trials scheduled for presentation at the 2023 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting taking place from October 23 to 26 in San Francisco. TCT is renowned for showcasing groundbreaking research in…
View more
Added:
2 weeks ago
TCT 2025 - In this insightful highlights video from TCT 2025, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, SA) provides expert commentary on the most impactful late-breaking clinical trials presented at this year's conference.The commentary distills the most important late-breaking trials in structural cardiology, coronary interventions, and artificial intelligence presented at TCT 2025…
View more
Added:
5 days ago
AHA Scientific Sessions 2025 - Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) joins us to discuss the evolving understanding of the causal relationship between elevated lipoprotein(a) and atherosclerotic cardiovascular disease, and what this means for risk stratification and management strategies in clinical practice.Dr O'Donoghue begins by highlighting the importance for clinicians to…
View more
Added:
2 weeks ago
TCT 2025 - In this comprehensive highlights video from TCT 2025, Prof Rasha Al-Lamee (Imperial College Healthcare NHS Trust, UK) delivers an expert analysis of the groundbreaking late-breaking trials that are set to reshape interventional cardiology practice.Join Prof Al-Lamee as she breaks down the pivotal studies driving innovation in cardiovascular care and discusses their implications for…
View more
Added:
2 weeks ago
Source:
Radcliffe Cardiology
The optimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) requires a careful balance between reducing ischaemic events and minimising bleeding risk. The HOST-BR trial was designed to evaluate the ideal DAPT duration in patients stratified by their bleeding risk.¹This open-label, multicentre, randomised clinical trial enrolled 4,897 patients who…
View more
Added:
2 weeks ago
TCT 2025 - Dr Nadira Hamid (Allina Health Minneapolis Heart Institute, Minneapolis, US) is joined by Dr Jonathan Schwartz (Sanger Heart and Vascular Institute, Charlotte, US) to discuss the lessons learned from the update of the TRILUMINATE Pivotal Trial (NCT03904147), investigating tricuspid TEER (transcatheter edge-to-edge repair) in 800+ patients with severe tricuspid regurgitation.Findings at…
View more
Added:
2 months ago
Source:
TCT Conference 2025 Programme Guide
Late-breaking clinical trials and science sessions have been announced for Transcatheter Cardiovascular Therapeutics 2025 conference.The conference is set to take place from 25th to 28th October 2025 at the Moscone Center in San Francisco, CA.Access the full programme here.Late-Breaking Clinical Trials: Session I, in Collaboration with The LancetSunday 26th October, 11:00am – 12:28pm (PDT)One…
View more
Added:
1 month ago
Source:
Transcatheter Academy
The long-term durability of complete revascularization in older patients with myocardial infarction (MI) and multivessel disease has been a subject of recent debate. New 3-year follow-up data from the Functional Assessment in Elderly MI Patients With Multivessel Disease (FIRE) trial show that the clinical benefits of a physiology-guided complete revascularization strategy are sustained over time…
View more
Added:
1 year ago